​

Lyell Immunopharma Ownership | Who Owns Lyell Immunopharma?


OverviewForecastRevenueFinancialsChart

Lyell Immunopharma Ownership Summary


Lyell Immunopharma is owned by 51.72% institutional investors, 28.62% insiders, and 19.66% retail investors. Arch venture management is the largest institutional shareholder, holding 19.00% of LYEL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.84% of its assets in Lyell Immunopharma shares.

LYEL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockLyell Immunopharma51.72%28.62%19.66%
SectorHealthcare Stocks 129.28%12.06%-41.34%
IndustryBiotech Stocks 181.42%11.67%-93.09%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Arch venture management3.25M19.00%$65.14M
Gsk1.51M6.47%$14.81M
Blackrock13.50M5.31%$19.57M
Vanguard group826.43K4.52%$25.44M
Blackrock funding, inc. /de799.06K3.42%$7.82M
Almitas capital577.81K3.38%$11.59M
Orland properties754.70K3.23%$7.39M
Vanguard capital management748.85K3.21%$7.33M
Wuxi apptec7.68M3.02%$11.14M
Foresite capital management v477.08K2.79%$9.57M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Wuxi apptec7.68M47.74%$11.14M
Arch venture management3.25M9.62%$65.14M
Orland properties754.70K4.97%$7.39M
Foresite capital management v477.08K3.53%$9.57M
Gsk1.51M2.98%$14.81M
Almitas capital577.81K2.62%$11.59M
Venbio partners337.70K2.41%$6.77M
Takeda pharmaceutical41.16K1.86%$363.91K
Decheng capital595.47K1.33%$5.26M
Velan capital investment management lp102.00K1.28%$2.05M

Top Buyers

HolderShares% AssetsChange
D. e. shaw966.26K0.00%493.64K
Arch venture management3.25M9.62%488.09K
Millennium management458.90K0.00%400.25K
Wellington management group llp367.68K0.00%367.68K
Velan capital investment management lp102.00K1.28%102.00K

Top Sellers

HolderShares% AssetsChange
Decheng capital595.47K1.33%-11.31M
Balyasny asset management---1.20M
Mwg management---1.01M
Invenomic capital management lp---871.52K
Foresite capital management iv---800.40K

New Positions

HolderShares% AssetsChangeValue
Wellington management group llp367.68K0.00%367.68K$533.13K
Velan capital investment management lp102.00K1.28%102.00K$2.05M
Opaleye management79.10K0.21%79.10K$1.59M
Empowered funds25.17K0.00%25.17K$246.42K
Creative planning24.67K0.00%24.67K$241.53K

Sold Out

HolderChange
Pnc financial services group-4.00
True wealth design-23.00
Nelson, van denburg & campbell wealth management group-34.00
Allworth financial lp-43.00
Daiwa securities group-45.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2026998.79%12,083,270-0.06%511.93%553.77%2321.05%
Jun 30, 20269119.74%12,089,9560.96%511.73%5323.26%19111.11%
Mar 31, 2026768.57%11,974,5454.99%701.80%4334.38%9-47.06%
Dec 31, 202510-82.76%864,633-91.03%40.11%4-80.00%2-89.47%
Sep 30, 202515-78.26%1,180,540-87.25%70.20%6-50.00%4-92.86%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv604.46K2.84%67.20K
Vanguard Morn Total Stk Mkt Idx Investor604.46K2.47%67.20K
Vanguard MStar Total Stk Mkt Idx Invest604.46K2.47%-
T. Rowe Price Health Sciences212.18K1.10%-2.38K
Biotech Growth Ord2.88M0.99%-
iShares Russell 2000 ETF221.96K0.90%-
Vanguard Small Cap Index2.24M0.87%5.37K
Vanguard Institutional Extnd Mkt Idx Tr163.75K0.70%-
Vanguard Small Cap Growth Index Inv1.25M0.49%-5.54K
Fidelity Small Cap Index107.31K0.44%3.75K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 10, 2026Lee Gary K. Chief Scientific OfficerSell$2.05K
Nov 10, 2026Hill Stephen J. Chief Operating OfficerSell$1.40K
Nov 10, 2026Seely Lynn President and CEOSell$8.68K
Nov 10, 2026Bulis Veronica Sanchez VP, Corporate ControllerSell$6.63K
Nov 04, 2026ARCH Venture Partners IX, LLC-Buy$25.00M

Insider Transactions Trends


DateBuySell
2026 Q425
2026 Q3-10
2026 Q2-5
2026 Q127
2025 Q4-6

LYEL Ownership FAQ


Who Owns Lyell Immunopharma?

Lyell Immunopharma shareholders are primarily institutional investors at 51.72%, followed by 28.62% insiders and 19.66% retail investors. The average institutional ownership in Lyell Immunopharma's industry, Biotech Stocks , is 181.42%, which Lyell Immunopharma falls below.

Who owns the most shares of Lyell Immunopharma?

Lyell Immunopharma’s largest shareholders are Arch venture management (3.25M shares, 19.00%), Gsk (1.51M shares, 6.47%), and Blackrock (13.5M shares, 5.31%). Together, they hold 30.78% of Lyell Immunopharma’s total shares outstanding.

Does Blackrock own Lyell Immunopharma?

Yes, BlackRock owns 5.31% of Lyell Immunopharma, totaling 13.5M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.57M$. In the last quarter, BlackRock decreased its holdings by -397K shares, a -2.86% change.

Who is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested?

Wuxi apptec is Lyell Immunopharma’s biggest shareholder by percentage of total assets invested, with 47.74% of its assets in 7.68M Lyell Immunopharma shares, valued at 11.14M$.

Who is the top mutual fund holder of Lyell Immunopharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Lyell Immunopharma shares, with 2.84% of its total shares outstanding invested in 604.46K Lyell Immunopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools